Neurofeedback as a Treatment Tool for Depression (NFD)
fMRI Based Neurofeedback as a Treatment Method for Depression
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Wales
-
Cardiff, Wales, Royaume-Uni, CF14 4XN
- School of Medicine, Cardiff University
-
Cardiff, Wales, Royaume-Uni, CF103AT
- CUBRIC
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- major depressive disorder (MDD) diagnosis
- stable antidepressant dose medication
Exclusion Criteria:
- Other physical or psychiatric disorders
- Current substance abuse
- Current psychotherapy or other specific intervention
- Exclusion criteria applicable to MRI
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Emotion network up-regulation
Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
|
5 sessions lasting one hour each
|
|
Comparateur actif: Place processing network up-regulation
Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
|
5 sessions lasting one hour each
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at the end of intervention (after 5th session)
Délai: Before start trial (baseline), after intervention (appr. 2 months)
|
Before start trial (baseline), after intervention (appr. 2 months)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
Change from Baseline in the Quality of Life Scale (QOLS) at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
Change from Baseline in the Quality of Life Scale (QOLS) at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in the Self-efficacy-scale (general subscale: GSE) at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
|
Change from Baseline in the Self-efficacy-scale (general subscale: GSE) at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
|
Change from Baseline in the Self-efficacy-scale (social subscale: SSE) at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
|
Change from Baseline in the Self-efficacy-scale (social subscale: SSE) at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
|
Change from Baseline in the Thought control questionnaire (TCQ) at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
|
Change from Baseline in the Thought control questionnaire (TCQ) at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
|
Change from Baseline in the Thought control ability questionnaire (TCAQ) at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
|
Change from Baseline in the Thought control ability questionnaire (TCAQ) at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
|
Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BAS scale, at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
|
Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BAS scale, at follow-up
Délai: Baseline, 3-month follow-up
|
Baseline, 3-month follow-up
|
|
|
Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BIS scale, at the end of intervention (after 5th session)
Délai: Baseline, end of intervention (appr. 2 months)
|
Baseline, end of intervention (appr. 2 months)
|
|
|
Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BIS scale, at follow-up
Délai: Baseline, 3-months follow-up
|
Baseline, 3-months follow-up
|
|
|
Change from Baseline in health service resource use as measured with a Resource Use Questionnaire
Délai: Baseline, 3-months follow-up
|
Baseline, 3-months follow-up
|
|
|
Change from before to after scan in the Profile of Mood States (POMS)
Délai: Before and after each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)
|
Measure to address any imminent changes in mood state.
|
Before and after each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)
|
|
Relation between upregulation ability of target areas (as obtained by functional MRI analysis) and perceived self control
Délai: Integrating imaging and psychometric data across the intervention period (appr. 2 months)
|
Analysis of the relationship between scores on the self-efficacy scales, thought control questionnaire (TCQ), thought control ability questionnaire (TCAQ) and the behavioural inhibition system and behavioural activation system (BIS/BAS) scales and fMRI data.
|
Integrating imaging and psychometric data across the intervention period (appr. 2 months)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: David E Linden, MD, Cardiff University
Publications et liens utiles
Publications générales
- Johnston SJ, Boehm SG, Healy D, Goebel R, Linden DE. Neurofeedback: A promising tool for the self-regulation of emotion networks. Neuroimage. 2010 Jan 1;49(1):1066-72. doi: 10.1016/j.neuroimage.2009.07.056. Epub 2009 Jul 29.
- Johnston S, Linden DE, Healy D, Goebel R, Habes I, Boehm SG. Upregulation of emotion areas through neurofeedback with a focus on positive mood. Cogn Affect Behav Neurosci. 2011 Mar;11(1):44-51. doi: 10.3758/s13415-010-0010-1.
- Fovet T, Jardri R, Linden D. Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms. Curr Pharm Des. 2015;21(23):3384-94. doi: 10.2174/1381612821666150619092540.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- SPON927-11
- G 1100629 (Autre subvention/numéro de financement: MRC)
- HS/10/25 (Autre subvention/numéro de financement: NISCHR)
- 11/WA/0106 (Autre identifiant: NHS Research Ethics Committee)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .